

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

January 26, 2022

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G-Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to submit that the Board of Directors of J. B. Chemicals & Pharmaceuticals Limited (**JBCPL**) at its meeting held on 25 January 2022 has considered and approved the acquisition of a portfolio of brands, for use and commercialization within India, from Sanzyme Private Limited (**SPL**).

Enclosed as Annexure-I is the information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to this acquisition.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President - Secretarial
& Company Secretary



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

ANNEXURE - I


Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No.	Particulars	Disclosure
1.	Name of the target entity from whom the assets are taken over, details in brief such as size, turnover etc.	Portfolio of brands, for use and commercialization within India, of Sanzyme Private Ltd (SPL), an Indian company engaged in the business of procurement, manufacture, marketing, sale and distribution of probiotic, therapeutic nutraceutical and reproductive health products. The turnover* of these brands for FY 2020-21 was Rs. 88 crores (impacted by COVID) and Rs.75 crores for H1 FY 2021-22
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquired brands will fit well with JBCPL's overall strategy of building diversified pharmaceutical business in India comprising of high-quality brands. Post the transaction, JBCPL would be able to further scale up and institutionalize the acquired brands within the territory of India.

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government/ regulatory approvals are required
6.	Indicative time period for completion of the acquisition	The conditions precedent to the acquisition are expected to be completed by February 2022
7.	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration payable by JBCPL to SPL
8.	Cost of acquisition or the price at which the shares are acquired	~Rs. 628 Crores (excluding related taxes, stamp duty and working capital)
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The brands being acquired from SPL comprise a range of probiotic, therapeutic nutraceutical and reproductive health products with attractive set of brands for use and exploitation within India. SPL's turnover over the past 3 financial years (as per its audited financial statements) is as follows: FY 2020-21: Rs. 130 Cr FY 2019-20: Rs. 194 Cr FY 2018-19: Rs. 172 Cr

*Turnover for brands are based on internal management reporting

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380